Nachrichten zur Akebia Therapeutics Aktie

Akebia Therapeutics, Inc.: 8-K Report

8-K...…

Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference

Um den gesamten Artikel unter barchart.com zu lesen, klicken Sie bitte auf die Überschrift...…

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. , Jan. 5, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. …

Akebia Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 4, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. …

Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately....…

Akebia Therapeutics, Inc.: 8-K Report

8-K...…

Akebia Therapeutics, Inc.: 8-K Report

8-K...…

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. , Dec. 2, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. …

The Play On Akebia Now

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Akebia Therapeutics, Inc.: 10-Q Report

10-Q...…

Akebia Therapeutics, Inc.: 8-K Report

8-K...…

Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates

CAMBRIDGE, Mass. , Nov. 5, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical…

Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights

CAMBRIDGE, Mass. , Oct. 26, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. …

Akebia announces additional vadadustat data in non-dialysis patients

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Seth Klarman Axes Akebia Therapeutics Stake From Portfolio

Gurus firm divests of holding in biotech company focusing on kidney disease...…

Thinking about buying stock in Akebia Therapeutics, Aileron Therapeutics, Riot Blockchain, Plug Power, or Translate Bio?

NEW YORK , Oct. 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKBA,…

Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined

CAMBRIDGE, Mass. , Oct. 9, 2020 /PRNewswire/ -- …

Akebia Therapeutics, Inc.: 8-K Report

8-K...…

Akebia Therapeutics, Inc.: 8-K Report

8-K...…

Akebia Therapeutics Announces September 2020 Investor Conference Schedule

CAMBRIDGE, Mass. , Sept. 8, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. …

Akebia Anemia Data, And Other News: The Good, Bad And Ugly Of Biopharma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Akebia Falls as Vadadustat Fails to Meet Safety Endpoint

Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due…

Top Analyst Upgrades and Downgrades: Akebia, Broadcom, DocuSign, Lululemon, NextEra, Overstock.com, Shopify, Wayfair and More

Um den gesamten Artikel unter feedproxy.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Akebia Therapeutics, Inc.: 8-K Report

8-K...…

Why Akebia Therapeutics Stock Is Crashing Today

The companys lead pipeline candidate fell short in a late-stage clinical study....…

Fulgent Genetics leads healthcare gainers; Akebia Therapeutics and NanoViricides among losers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ROCE Insights For Akebia Therapeutics

In Q2, Akebia Therapeutics (NASDAQ: AKBA) posted sales of $90.14 million. Earnings were up 193.99%, but Akebia Therapeutics still reported…

Akebia down big after vadadustat misses safety endpoints in late-stage studies in CKD anemia

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis

CAMBRIDGE, Mass. , Sept. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. …

Akebia Announces Initiation of Investigator-Sponsored Study Evaluating Vadadustat for Prevention and Treatment of ARDS in Patients Hospitalized with COVID-19

CAMBRIDGE, Mass. , July 14, 2020 /PRNewswire/ -- Akebia Therapeutics …

Akebia Therapeutics Announces Data on Different Dosing Regimens of Ferric Citrate for Iron Deficiency Anemia Presented at 57th ERA-EDTA Virtual Congress

CAMBRIDGE, Mass. , June 10, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. …